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Abstract
Performances of cationic lipid formulations for intravenous gene delivery to mouse lungs have been previously reported.
We report in this study that cationic phosphonolipids, when appropriately formulated, can be good synthetic vectors for gene
delivery to lung after intravenous administration. One of our reagents, GLB43, was capable of mediating a 500-fold higher
expression in the lungs of mice than could be obtained with free pDNA alone (P = 0.018). We demonstrate that the most
important parameters for cationic phosphonolipid transfection activity after systemic administration are the chemical
structure of the cationic phosphonolipid, the lipid to DNA charge ratio and the inclusion of co-lipid in the formulation. We
report using a luciferase reporter gene that transfection activity in vivo 24 h after cationic phosphonolipid systemic
administration could not be predicted from in vitro analysis. In contrast to in vitro studies, cationic phosphonolipids
including the oleyl acyl chains (GLB43) were more effective than its analogue with the myristyl acyl chains (GLB73). Using
pathological analysis of animal livers, we demonstrate that the toxicity level was correlated with the lipoplex formulation and
the lipid to DNA ratio. ß 2000 Elsevier Science B.V. All rights reserved.
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1. Introduction
Cationic lipids and recombinant DNA complexes
(lipoplexes) have proved useful in many in vitro and
in vivo animal model applications and recently have
been optimised with the results of the ¢rst cationic
lipid gene therapy trials [1^4]. A large number of
families of cationic vectors have now been synthe-
sised. Whilst the concept of transfecting with lipid/
DNA complexes is simple, we still need to improve
their transfection e⁄ciency, increase their targeted
delivery and improve their transient gene expression;
this is particularly true for their use in in vivo pro-
tocols for gene transfer. Intravenous administration
of lipoplexes has been previously described as e⁄-
cient to transfect lung tissue [5,6]. Two recent studies
[7,8] reported transgene expression in pulmonary epi-
thelial cells (type II alveolar epithelial cells) after
systemic delivery of cationic lipid/DNA complexes.
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These data led us to think that intravenous delivery
could be a potential mode of administration for the
gene therapy of lung diseases, particularly cystic ¢-
brosis (CF). Moreover, Griesenbach et al. [7] re-
ported that it has been suggested that the CF trans-
membrane regulator (CFTR) is expressed in alveolar
type II cells [9], so these cells might be suitable target
cells for CF gene therapy. Previously, we have syn-
thesised a novel class of cationic lipids called cationic
phosphonolipids [10], and have described the ability
of these vectors to transfer DNA into an immortal-
ised CF airway epithelial cell line (CFT1 cells) [11].
Recently Guillaume et al. [12] reported signi¢cant
data about the transfection e⁄ciency in mouse lungs
after intratracheal administration of the cationic
phosphonolipids known as GLB73 and 43, their
good transfection e⁄ciency was demonstrated in
comparison with DC-Chol. Here, we report that cat-
ionic phosphonolipids are also e¡ective in transfect-
ing lung cells in vivo after systemic administration.
Using two types of cationic phosphonolipids di¡er-
ing only in their aliphatic chain length (GLB73
C14:0 and GLB43 C18:1), we demonstrate that there
is a relationship between the chemical structure of
cationic phosphonolipids and their transfection e⁄-
ciency in vivo. Using lipoplexes which include DOPE
or cholesterol as a co-lipid, we show that transfection
e⁄ciency in vivo is dependent on the neutral lipid
included in the cationic phosphonolipid/DNA com-
plex formulation and lipid to DNA ratio. In our
experiments, transfection activity in mouse lungs
24 h after cationic phosphonolipid systemic admin-
istration could not be predicted from in vitro analysis
using the human CFT1 cell line. In a recent study,
Song et al. [13] reported that high transfection activ-
ity after intravenous administration of DOTMA
lipoplexes was correlated with a high toxicity. They
reported that liver necrosis may be the main reason
for such toxicity. These data led us to evaluate hepa-
tic toxicity of our compounds after systemic admin-
istration. Using pathological analysis of animal liv-
ers, we demonstrate that the toxicity level was
correlated with the lipoplex formulation and the lipid
to DNA ratio. We suggest that an optimal set of
conditions which include cholesterol as the co-lipid,
resulting in good expression in the lung and no
hepatic toxicity, could be proposed for intravenous
cationic phosphonolipid-mediated gene delivery.
2. Materials and methods
2.1. Cell lines and plasmid DNA
For the in vitro experiments we used the CFT1 cell
line. CFT1 cells are SV40 large T-transformed CF
tracheal cells obtained from a CF foetus after ther-
apeutic abortion [14]. They were grown in MEM/
Ham F-12 (50/50) medium supplemented with 10%
of foetal calf serum (FCS), 0.2 mM glutamine,
100 U/ml penicillin, 100 Wg/ml streptomycin and
1% fungizone. The plasmid used was pTG11033 (a
gift from TRANSGENE, Strasbourg, France) en-
coding luciferase protein.
2.2. Preparation of cationic phosphonolipid/DNA
complexes
Cationic phosphonolipids used in this report were
synthesised by our group. These original molecules
were obtained by the Mannich reaction from fatty
phosphites followed by quaternarisation of the re-
sulting aminophosphonates [10]. Their structures
are presented in Fig. 1. Each of the cationic phos-
phonolipids was prepared alone or in combination
with the neutral lipid DOPE or cholesterol (Sigma,
Saint Quentin Fallavier, France) as described else-
where [15].
2.3. Transfection of CFT1 cells and reporter gene
assay
Transfection activity of the cationic lipid/DNA
complexes in vitro was assessed using CFT1 cells as
described elsewhere [15]. Following a further 48 h at
37‡C, the cells were assayed for luciferase expression
using a chemiluminescent assay (Promega). Assays
were carried out as described by the manufacturer.
Fig. 1. Structure of cationic phosphonolipids.
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The results are expressed in TRLU (total relative
light units obtained for 16 wells).
2.4. Intravenous gene delivery and luciferase
expression in mouse tissues
Cationic phosphonolipid/pTG11033 plasmid DNA
complexes were delivered by a single injection of 200
Wl in the tail vein of 6-week-old female Swiss mice,
each animal received 50 Wg of plasmid DNA. Ani-
mals were killed 24 h after injection and mouse tis-
sues were immediately frozen on dry ice and stored
at 370‡C until examined. Luciferase activity was as-
sayed using a chemiluminescent kit (Promega). Ex-
traction of luciferase from mouse tissues was carried
out as described by Thierry et al. [5]. The total pro-
tein concentration of the tissue extract was deter-
mined using the Bio-Rad protein assay. Luciferase
activity of each sample was normalised to relative
light units (RLU) per mg of extracted protein.
2.5. Determination of charge ratio of lipoplex
The charge ratio was theoretically calculated as
molar ratio of GLB compounds (one positive charge
per molecule) to nucleotide residue (average MW
330).
2.6. Microscopic study of hepatic toxicity
Mice were killed 24 h after intravenous injection.
Livers were excised and immediately ¢xed in Bouin
¢xative solution for 24^48 h. They were then pro-
cessed by usual methods of para⁄n embedding sec-
tions and stained with haematoxylin and eosin. Sec-
tions were examined with a photonic microscope.
2.7. Statistical analysis
Results are reported as means þ S.E.M. The stat-
istical signi¢cance of the data was determined with
Student’s unpaired t-test as appropriate. P6 0.05
was considered signi¢cant.
3. Results
3.1. In£uence of cationic phosphonolipid to DNA ratio
and formulation on transfection e⁄ciency in vivo
In vitro experiments demonstrate the in£uence of
di¡erent parameters on cationic lipid-mediated gene
transfer in cell lines [16^18]. Among these, lipid to
DNA ratio has been shown to be an important fac-
tor. To evaluate the in£uence of the lipoplex charge
ratio on in vivo transfection activity after intrave-
nous administration, 50 Wg of pTG11033 plasmid
containing ¢re£y luciferase cDNA driven by a
CMV promoter was complexed with di¡erent quan-
tities of GLB43 cationic phosphonolipid and injected
into mice via the tail vein. Di¡erent formulations
were used, including GLB43/DOPE (1:1, w/w),
GLB43/Chol (1:1, w/w) and GLB43 alone, at 0.8:1,
1:1, 2:1, 4:1 and 6:1 (+/3) charge ratio. The lucif-
erase activity detected in the lungs 24 h after intra-
venous administration is presented in Fig. 2. No re-
porter gene expression was observed in the liver or
spleen regardless of the formulation or the charge
ratio used (data not shown). In the lung, luciferase
activity increased as the lipoplex charge ratio in-
creased to 4, for all the formulations used. The high-
est luciferase activity was obtained with a lipid to
DNA ratio of 4. With this optimal condition, and
using an appropriate formulation, GLB43 was capa-
ble of mediating a 500-fold greater expression in the
lung than could be obtained with free pDNA alone
Fig. 2. In£uence of cationic phosphonolipid to DNA ratio and
cationic phosphonolipid formulation on transfection e⁄ciency
in vivo. Twenty-four hours after intravenous administration of
50 Wg of pTG11033 DNA plasmid complexed with the indi-
cated amount of the lipoplexes GLB43, GLB43/DOPE (1:1)
and GLB43/Chol (1:1), luciferase activity was assayed in mouse
lungs. In the control group, mice received only naked DNA.
R = calculated charge ratio of the lipoplex. The data are pre-
sented as mean þ S.E.M. (n = 10).
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(P = 0.018). With a ratio at 6, a noticeable decrease
in activity was observed suggesting that an excess of
positive charges may result in a toxic e¡ect.
Although the role of the neutral co-lipid in the
cationic lipid/DNA complex has not been well de-
¢ned, several authors [16,17] have reported that the
inclusion of DOPE in the cationic lipid formulation
increases transfection activity by enhancing the mix-
ing and fusion of liposomes and cell membranes.
DOPE forms inverted hexagonal phase structures
at ambient temperature [19,20], and may therefore
facilitate the formation of similar structures when
formulated with cytofectins [21]. Recent data have
demonstrated that including cholesterol in the cati-
onic lipid formulation improves in vivo transfection
activity [22,23]. Therefore, we examined the role of
the neutral co-lipids DOPE and cholesterol in im-
proving the in vivo transfection e⁄ciency of the cat-
ionic phosphonolipid GLB43. Three di¡erent formu-
lations (GLB43 alone, GLB43/DOPE and GLB43/
Chol) were complexed with 50 Wg of pTG11033 plas-
mid and injected into mice. Five lipid to DNA
charge ratios (0.8, 1, 2, 4 and 6) were tested. Results
of luciferase activity observed in the lung 24 h after
intravenous administration are presented in Fig. 2.
For each of the lipid to DNA ratios used, the inclu-
sion of co-lipid (DOPE or cholesterol) in the GLB43
formulation decreased its transfection activity in
lungs of mice after intravenous administration and
the results of transfection e⁄ciency observed were
equivalent whatever the amounts of co-lipid used
(data not shown). However, although the maximal
level of luciferase expression was obtained using
GLB43 alone, the inclusion of cholesterol in this cat-
ionic phosphonolipid formulation allowed us to ob-
tain a level of luciferase expression 100-fold greater
than with free pDNA alone (P = 0.006). No trans-
fection activity was observed using DOPE as co-lipid
in the GLB43 formulations.
3.2. In£uence of cationic phosphonolipid aliphatic
chain length on transfection e⁄ciency in vivo
The e¡ect of the aliphatic chain length of cationic
phosphonolipids on transfection activity 24 h after
intravenous administration to mice of 50 Wg of
pTG11033 plasmid was investigated using two di¡er-
ent compounds, GLB43 (C18:1) and GLB73
(C14:0), at di¡erent charge ratios and using di¡erent
formulations (alone, with DOPE (1:1), and with cho-
lesterol (1:1)). The results obtained using the GLB43
formulations were presented above (Fig. 2). Results
of transgene expression obtained in mouse lungs us-
Fig. 3. E¡ect of di-myristyl fatty acyl chain of cationic phos-
phonolipid on transfection e⁄ciency in vivo. Luciferase activity
was assayed in mouse lungs 24 h after intravenous administra-
tion of 50 Wg of pTG11033 DNA plasmid complexed with vari-
ous amounts of lipoplexes composed of GLB73 (C14:0) formu-
lated with or without co-lipid. In the control group, mice
received only naked DNA. The data are presented as mean þ
S.E.M. (n = 8).
C
Fig. 4. E¡ect of cationic phosphonolipid/DNA ratio (R) and lipoplex formulation on in vivo toxicity. Histological analysis of mouse
livers 24 h after transfection. Arrows indicate necrotic hepatocytes. Haematoxylin-eosin stain. (A) Injection of 50 Wg of pDNA alone
(magni¢cation U18). No abnormality was observed. (B) Injection of GLB43/plasmid DNA, R = 0.8 (magni¢cation U18). Very rare
necrotic hepatocytes scattered in the hepatic lobule. Inset: detail of necrosis (magni¢cation U115). (C) Injection of GLB43/plasmid
DNA, R = 1 (magni¢cation U18). Rare necrotic hepatocytes scattered in the liver lobule. Inset: detail of necrotic cells with a slight in-
£ammatory reaction (magni¢cation U115). (D) Injection of GLB43/plasmid DNA, R = 2 (magni¢cation U45). Several aggregates of
necrotic hepatocytes, arrows delineate the zone of necrosis. (E) Injection of GLB43/plasmid DNA, R = 4 (magni¢cation U18). Fields
of necrotic cells are much more numerous and larger. Inset: detail of aggregate of necrotic cells (magni¢cation U115). (F) Injection
of GLB43/plasmid DNA, R = 6 (magni¢cation U18). Very large lesions made up of a con£uent area of necrotic cells. (G) Injection of
GLB43 DOPE/plasmid DNA, R = 4 (magni¢cation U45). Very rare necrotic cells with very slight lipid accumulation. (H) Injection of
GLB43 cholesterol/plasmid DNA, R = 4 (magni¢cation U45). Isolated necrotic cells with slight lipid accumulation.
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ing the GLB73 formulations are presented in Fig. 3.
In general, regardless of the formulation used, it ap-
pears that GLB73 (C14:0) was less e¡ective than
GLB43 (C18:1). Moreover, in contrast to GLB43,
GLB73 needed to be used with a co-lipid to present
a weak transfection activity in the lungs 24 h after
intravenous administration. With this compound, the
maximal level of luciferase expression was obtained
using DOPE as co-lipid and with a lipid to DNA
ratio of 2 (P = 0.0195).
3.3. E¡ect of cationic lipid/DNA ratio and lipoplex
formulation on in vivo toxicity
Hepatic toxicity has been reported after systemic
administration of lipoplexes [13]. In order to study
the toxic e¡ects of cationic phosphonolipid-mediated
gene transfer after intravenous delivery, systematic
pathological analysis of the liver was carried out.
No toxicity was observed after injection of formula-
tions including DOPE as a co-lipid or using pDNA
alone (Fig. 4A,G). When GLB43 was injected with-
out co-lipid, liver necrosis was observed with the
severity of lesions increasing according to the cati-
onic phosphonolipid/DNA ratio (Fig. 4B^F). Inclu-
sion of cholesterol in the GLB43 formulations al-
lowed us to decrease the liver toxicity of the
formulation (Fig. 4H). These observations suggest
that cationic phosphonolipid metabolites may play
a key role in the toxicity process. Further experi-
ments injecting these di¡erent metabolites are neces-
sary in order to understand this toxicity and to help
improve the chemical design of our molecules. No
toxicity was observed after intravenous administra-
tion of the GLB73 formulations.
3.4. Comparison of cationic phosphonolipid-mediated
gene transfer activity in vitro and in vivo
Transfection activity of the di¡erent GLB43 and
GLB73 formulations/pTG11033 complexes in vitro
was assessed using the immortalised CF epithelial
cell line CFT1. Results of luciferase activity observed
48 h after transfection are presented in Fig. 5A. As
was previously described [11,16,24], when DOPE was
absent from the phosphonolipid formulations only
weak transfection activity was observed. Inclusion
of cholesterol in the formulation improved transfec-
tion activity of GLB43 and GLB73 in vitro, but the
results obtained were inferior to those observed in
Fig. 5. Comparison of cationic phosphonolipid-mediated gene transfer activity in vitro and in vivo. (A) Comparison of GLB43 and
GLB73 formulations in in vitro transfection assays carried out on a CFT1 cell population with pTG11033 plasmid DNA. Two days
after transfection, luciferase activity was determined with a luminescent assay. Each data point indicates the mean value of total RLU
derived from three transfections and the standard error of this mean. (B) Comparison of GLB43 and GLB73 formulations, complexed
with 50 Wg of pTG11033 DNA plasmid, in transfection of mouse lungs after intravenous administration. Cationic phosphonolipid to
DNA ratios used were 2:1 for GLB73 and 4:1 for GLB43. S.E.M. is calculated from 10 mice for GLB43 and eight mice for GLB73.
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the presence of DOPE. In vitro, the phosphonolipid
with the di-myristyl fatty acyl chain had the most
e⁄cient level of transfection. Results obtained in
vivo after intravenous administration of the two
phosphonolipid formulations/pTG11033 are pre-
sented in Fig. 5BB In this case, in contrast to in vitro
studies, the best results were obtained with the
GLB43 compound and when co-lipid was absent
from the formulation.
4. Discussion
In contrast to in vitro studies, many groups have
reported low transfection e⁄ciencies for cationic lip-
ids in vivo especially in the gene therapy of CF [2^
4,25]. In most CF studies the lung was directly tar-
geted by local administration of the lipoplex (aerosol,
intratracheal and nasal instillation) and the thick
mucus accumulation observed in CF patients could
decrease lipoplex uptake by the airway epithelium
[7]. Performances of cationic lipid formulations for
intravenous gene delivery to mouse lungs have been
previously reported [5,6]. We report in this study that
cationic phosphonolipids, when appropriately formu-
lated, can be good synthetic vectors for gene delivery
to lung after intravenous administration. One of our
reagents, GLB43, was capable of mediating a 500-
fold higher expression in the lungs of mice than
could be obtained with free pDNA alone
(P = 0.018). The good transfection e⁄ciency obtained
using GLB43 could be explained by the characteristic
chemical structure of this compound. In fact, in or-
der to approach the chemical structure of natural
phospholipids, a phosphonate linker was included
between the polar head and the hydrophobic moiety
of the molecule. Moreover, this type of linker could
in£uence the biodegradability of the compound and
in this way may play an important role in transfec-
tion activity of this type of cationic lipid.
Among the parameters that in£uence gene transfer
activity of cationic lipids, including a neutral lipid in
the formulation has been described as playing a key
role. In most commercially available cationic lipid
formulations used for gene delivery DOPE is the
neutral component. Until recently, DOPE was de-
scribed as more e⁄cient than several other co-lipids
when included in cationic lipid formulations
[16,17,26^28]. Recent data have shown that gene
transfer mediated by the cationic lipid DOTAP was
more e⁄cient in vivo when cholesterol was used as
the co-lipid [22,23]. Moreover, recently Crook et al.
[29] reported that including cholesterol in DOTAP
transfection complexes increased the delivery of
DNA to cells in vitro in the presence of serum. Sev-
eral reasons have been suggested to explain the e¡ect
of cholesterol as a co-lipid. Crook et al. [29] suggest
that cholesterol maintains the transfection in the
presence of serum by improving cell binding and
uptake whilst Semple et al. [30] observed that the
half-life of liposomes in the circulation of mice can
be increased by including cholesterol in the formula-
tion. Lasic [31] and Papahadjopoulos [32] have also
discussed the role of cholesterol. Using GLB43 we
observed higher luciferase expression in mouse lungs
with cholesterol used as the co-lipid than with
DOPE. But, using our in vivo conditions, the best
results were still obtained using GLB43 alone. These
results are in agreement with those of Song et al. [13]
who reported that including helper lipid in DOTMA
liposomes decreased the level of in vivo gene expres-
sion. The decrease in transfection e⁄ciency of cati-
onic lipids in the presence of serum could be one
explanation of their low activity in vivo, which con-
sequently limits their in vivo applications. However,
the inhibitory e¡ect of serum on lipofection observed
in vitro can be overcome by increasing the charge
ratio of the cationic/lipid DNA complex [33]. We
observed this in vivo when, using GLB43 alone or
formulated with cholesterol, the optimal lipid to
DNA charge ratio was shown to be 4. No transfec-
tion activity was obtained with neutral or negatively
charged complexes. Mahato et al. [34] and Song et
al. [13] also reported that an excess of positive
charges was required for optimal transfection in
vivo. In our experiments only theoretically calculated
charge ratios were reported, therefore these observa-
tions need to be con¢rmed by determination of the j
potential of the lipoplexes.
In general, in vitro studies have shown that cati-
onic lipids exhibit signi¢cant toxicity. Thus, at higher
concentrations of cationic lipid, speci¢c transfection
is high but cells are lost, whilst at lower lipid con-
centrations both toxicity and transfection are mini-
mal [35,36]. In our experiments, pathological analy-
ses of transfected mouse livers were carried out. We
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observed that higher lipid to DNA charge ratios re-
sulted in serious toxic e¡ects which correlated with
increasing charge ratio, in agreement with the ¢nd-
ings of a previous study [13]. Hepatic necrosis was
particularly prevalent when cationic phosphonolipid
GLB43 was used without co-lipid. Inclusion of cho-
lesterol in the GLB43 formulation allowed us to ob-
tain both good transfection e⁄ciency and less toxic-
ity. No toxicity was observed after injection of
GLB43 or plasmid DNA alone. These results suggest
that cholesterol might decrease the toxic e¡ect of
cationic lipid and allow us to obtain good transfec-
tion e⁄ciency after intravenous administration.
Our results suggest that the activity of cationic
phosphonolipids for in vivo intravenous delivery
could not be predicted from the in vitro analysis.
They are consistent with those of Lee et al. [24]
who reported that the most e¡ective cationic lipid/
pDNA for in vitro transfection of CFT1 cells was in
general not similar to those for in vivo delivery to the
lung. Even though including co-lipid in the cationic
lipid formulation improved transfection activity in
vitro [16], with our experimental conditions the op-
posite e¡ect was observed in vivo. This observation
was in agreement with those of previous studies [13],
which suggested that the role of DOPE or cholesterol
in cationic lipid formulations was di¡erent in vivo
from in vitro. Our results describing the in£uence
of the structure of the hydrophobic moiety of the
phosphonolipid on transfection activity were not
consistent with the conclusions from previous studies
[37].
In summary, we have demonstrated that e⁄cient
transfection activity in mouse lungs can be achieved
after intravenous administration of cationic phos-
phonolipids. Further experimentation of immunohis-
tochemistry will be necessary to con¢rm the exact
localisation of the transgene expression in pulmonary
cells. The results obtained highlight that the activity
of cationic phosphonolipids for in vivo intravenous
delivery could not be predicted from the in vitro
analysis. Pathological analysis suggests that optimi-
sation of cationic phosphonolipid formulations is
necessary to obtain e⁄cient activity and less toxicity.
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